proxyvotesnow.com

Home › Companies › NEUROCRINE BIOSCIENCES INC. › 2024-2025

NEUROCRINE BIOSCIENCES INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and NEUROCRINE BIOSCIENCES INC.’s Form 8-K, filed 2025-05-22 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 22Reported items
  • 601Asset managers
  • 5,860Fund votes
  • 2025-05-21Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore NEUROCRINE BIOSCIENCES INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by NEUROCRINE BIOSCIENCES INC.

These tallies are NEUROCRINE BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-22 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

NEUROCRINE BIOSCIENCES INC. — official shareholder meeting results, meeting held 2025-05-21
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Kyle W. Gano, Ph.D. 84,346,100---- 1,382,6734,705,420 Majority: yes
Elect Director: Richard F. Pops 72,919,088---- 12,809,6854,705,420 Majority: yes
Elect Director: Shalini Sharp 79,466,551---- 6,262,2224,705,420 Majority: yes
Elect Director: Stephen A. Sherwin, M.D. 79,505,052---- 6,223,7214,705,420 Majority: yes
The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the 2025 Plan. 72,648,86212,884,104195,807 --4,705,420 Majority: yes
The 2025 Plan was approved. • Approval of the Amended and Restated ESPP. 85,402,588138,042188,143 --4,705,420 Majority: yes

Source: NEUROCRINE BIOSCIENCES INC., Form 8-K, filed with the SEC on 2025-05-22 — read the filing on EDGAR.

How asset managers voted at the NEUROCRINE BIOSCIENCES INC. 2024-2025 meeting

Each item below shows how the 601 asset managers that disclosed a NEUROCRINE BIOSCIENCES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NEUROCRINE BIOSCIENCES INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Advisory vote on the compensation paid to the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-05-21.

Combines 9 wordings of this item as funds reported it.

95% fund support · no official result

FOR 93%

The 561 asset managers below cast 95% of the shares they voted on this item FOR (86,912,932 for, 4,842,900 against).

FOR: 86,912,932 (93.4%)AGAINST: 4,842,900 (5.2%)ABSTAIN: 1,253,557 (1.3%)NOT VOTED: 2,700 (0.0%)
Largest asset managers voting on “Advisory vote on the compensation paid to the Company's named executive officers.” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock13,451,8230 00For
Vanguard11,909,436896 00For
Dodge & Cox9,715,5130 00For
State Street6,567,3350 00For
T. Rowe Price2,665,1870 00For
Fidelity1,941,0124,212 00For
GEODE CAPITAL MANAGEMENT, LLC1,928,8240 00For
Thrivent1,742,9720 00For
Wellington1,688,0430 00For
Charles Schwab1,581,6880 00For
DEERFIELD MANAGEMENT COMPANY, L.P.1,398,6930 00For
BNP Paribas Asset Management Holding S.A.00 1,167,2980Abstain
Renaissance1,078,4040 00For
ORBIMED ADVISORS LLC876,6200 00For
Northern Trust873,8610 00For
Invesco0837,113 00Against
Janus Henderson760,2160 00For
BROWN ADVISORY INC751,3300 00For
JENNISON ASSOCIATES LLC742,9390 00For
ARMISTICE CAPITAL, LLC733,4190 00For
MELLON INVESTMENTS Corp727,4710 00For
Allspring706,0510 00For
UBS632671,946 00Against
AQR661,1010 00For
Goldman Sachs659,0690 00For

Showing the 25 largest of 561 asset managers. See all 561 in the interactive database.

2. The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Kyle W. Gano, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-21.

Combines 9 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 84,346,100WITHHELD: 1,382,673

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Kyle W. Gano, Ph.D.”): 84,346,100 for, 1,382,673 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,000,000 outstanding shares: 85% for, 1% withheld (87% of the company cast a for/withheld vote).

The 140 asset managers below cast 100% of the shares they voted on this item FOR (40,682,411 for, 0 against).

FOR 99.7%
FOR: 40,682,411 (99.7%)ABSTAIN: 118,860 (0.3%)
Largest asset managers voting on “The election of the four nominees for Class II directors named below to the Board of Directors to serve for a ” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,700,1240 00For
BlackRock7,784,3920 00For
Dodge & Cox4,444,4630 00For
State Street1,958,6940 1210For
Fidelity1,848,6740 00For
T. Rowe Price1,123,7080 00For
Thrivent864,1570 00For
Charles Schwab762,8900 00For
CARILLON SERIES TRUST605,4520 00For
First Trust589,5860 00For
Prudential/PGIM577,7260 00For
JPMorgan554,4990 00For
JANUS INVESTMENT FUND428,3990 00For
Goldman Sachs357,8230 00For
Invesco352,1190 00For
Dimensional349,9760 00For
TIAA305,9380 00For
Allspring303,3050 00For
Jackson National297,7570 00For
Equitable274,8190 00For
Manager Directed Portfolios254,7200 00For
John Hancock246,2610 00For
AB DISCOVERY GROWTH FUND, INC.240,1760 00For
Brown Advisory Funds222,4140 00For
Aberdeen219,9120 00For

Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.

3. The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Richard F. Pops

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-21.

Combines 8 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%
FOR: 72,919,088WITHHELD: 12,809,685

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Richard F. Pops”): 72,919,088 for, 12,809,685 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,000,000 outstanding shares: 74% for, 13% withheld (87% of the company cast a for/withheld vote).

The 139 asset managers below cast 100% of the shares they voted on this item FOR (36,732,994 for, 0 against).

FOR 90%10%
FOR: 36,732,994 (90.1%)ABSTAIN: 4,043,077 (9.9%)
Largest asset managers voting on “The election of the four nominees for Class II directors named below to the Board of Directors to serve for a ” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,700,1230 10For
BlackRock7,784,3920 00For
Dodge & Cox4,444,4630 00For
State Street5,8510 1,952,9640Abstain
Fidelity1,848,6740 00For
T. Rowe Price00 1,123,7080Abstain
Thrivent864,1570 00For
Charles Schwab762,8900 00For
CARILLON SERIES TRUST605,4520 00For
First Trust589,5860 00For
Prudential/PGIM577,7260 00For
JPMorgan554,4990 00For
JANUS INVESTMENT FUND428,3990 00For
Goldman Sachs357,8230 00For
Invesco352,1190 00For
Dimensional349,9760 00For
TIAA305,9380 00For
Allspring303,3050 00For
Jackson National116,1300 181,6270Abstain
Equitable67,3460 207,4730Abstain
Manager Directed Portfolios254,7200 00For
John Hancock229,6020 16,6590For
AB DISCOVERY GROWTH FUND, INC.00 240,1760Abstain
Brown Advisory Funds222,4140 00For
Aberdeen219,9120 00For

Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.

4. The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Shalini Sharp

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-21.

Combines 8 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%
FOR: 79,466,551WITHHELD: 6,262,222

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Shalini Sharp”): 79,466,551 for, 6,262,222 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,000,000 outstanding shares: 80% for, 6% withheld (87% of the company cast a for/withheld vote).

The 139 asset managers below cast 100% of the shares they voted on this item FOR (39,027,545 for, 0 against).

FOR 96%
FOR: 39,027,545 (95.7%)ABSTAIN: 1,748,526 (4.3%)
Largest asset managers voting on “The election of the four nominees for Class II directors named below to the Board of Directors to serve for a ” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,700,1230 10For
BlackRock7,784,3920 00For
Dodge & Cox4,444,4630 00For
State Street1,958,8150 00For
Fidelity1,848,6740 00For
T. Rowe Price00 1,123,7080Abstain
Thrivent864,1570 00For
Charles Schwab762,8900 00For
CARILLON SERIES TRUST605,4520 00For
First Trust589,5860 00For
Prudential/PGIM577,7260 00For
JPMorgan554,4990 00For
JANUS INVESTMENT FUND428,3990 00For
Goldman Sachs357,8230 00For
Invesco352,1190 00For
Dimensional349,9760 00For
TIAA305,9380 00For
Allspring303,3050 00For
Jackson National297,7570 00For
Equitable67,3460 207,4730Abstain
Manager Directed Portfolios254,7200 00For
John Hancock229,6020 16,6590For
AB DISCOVERY GROWTH FUND, INC.00 240,1760Abstain
Brown Advisory Funds222,4140 00For
Aberdeen219,9120 00For

Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.

5. The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Stephen A. Sherwin, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-21.

Combines 9 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%
FOR: 79,505,052WITHHELD: 6,223,721

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Stephen A. Sherwin, M.D.”): 79,505,052 for, 6,223,721 withheld, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,000,000 outstanding shares: 80% for, 6% withheld (87% of the company cast a for/withheld vote).

The 139 asset managers below cast 100% of the shares they voted on this item FOR (38,986,995 for, 0 against).

FOR 96%
FOR: 38,986,995 (95.6%)ABSTAIN: 1,789,076 (4.4%)
Largest asset managers voting on “The election of the four nominees for Class II directors named below to the Board of Directors to serve for a ” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,700,1230 10For
BlackRock7,784,3920 00For
Dodge & Cox4,444,4630 00For
State Street1,958,6940 1210For
Fidelity1,848,6740 00For
T. Rowe Price00 1,123,7080Abstain
Thrivent864,1570 00For
Charles Schwab762,8900 00For
CARILLON SERIES TRUST605,4520 00For
First Trust589,5860 00For
Prudential/PGIM577,7260 00For
JPMorgan554,4990 00For
JANUS INVESTMENT FUND428,3990 00For
Goldman Sachs357,8230 00For
Invesco352,1190 00For
Dimensional349,9760 00For
TIAA305,9380 00For
Allspring303,3050 00For
Jackson National297,7570 00For
Equitable67,3460 207,4730Abstain
Manager Directed Portfolios254,7200 00For
John Hancock229,6020 16,6590For
AB DISCOVERY GROWTH FUND, INC.00 240,1760Abstain
Brown Advisory Funds222,4140 00For
Aberdeen219,9120 00For

Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.

6. To approve the Company's 2025 Equity Incentive Plan;

COMPENSATION

Meeting held 2025-05-21.

Combines 5 wordings of this item as funds reported it.

92% fund support · no official result

FOR 92%8%

The 139 asset managers below cast 92% of the shares they voted on this item FOR (37,411,942 for, 3,311,217 against).

FOR: 37,411,942 (91.9%)AGAINST: 3,311,217 (8.1%)ABSTAIN: 0 (0.0%)
Largest asset managers voting on “To approve the Company's 2025 Equity Incentive Plan;” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,699,890234 00For
BlackRock7,784,3920 00For
Dodge & Cox4,444,4630 00For
State Street5,8511,952,964 00Against
Fidelity1,679,954168,720 00For
T. Rowe Price1,123,7080 00For
Thrivent864,1570 00For
Charles Schwab762,8900 00For
CARILLON SERIES TRUST605,4520 00For
First Trust589,5860 00For
Prudential/PGIM68,470509,256 00Against
JPMorgan554,4990 00For
JANUS INVESTMENT FUND428,3990 00For
Goldman Sachs357,8230 00For
Invesco352,1190 00For
Dimensional349,9760 00For
TIAA305,9380 00For
Allspring303,3050 00For
Jackson National297,7570 00For
Equitable274,8190 00For
Manager Directed Portfolios254,7200 00For
John Hancock246,2610 00For
AB DISCOVERY GROWTH FUND, INC.240,1760 00For
Brown Advisory Funds222,4140 00For
Aberdeen219,9120 00For

Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.

7. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATED

Meeting held 2025-05-21.

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.7%

The 137 asset managers below cast 99.9% of the shares they voted on this item FOR (40,637,097 for, 30,485 against).

FOR: 40,637,097 (99.8%)AGAINST: 30,485 (0.1%)ABSTAIN: 52,286 (0.1%)
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,699,228896 00For
BlackRock7,784,3920 00For
Dodge & Cox4,444,4630 00For
State Street1,958,694121 00For
Fidelity1,848,6740 00For
T. Rowe Price1,123,7080 00For
Thrivent864,1570 00For
Charles Schwab762,8900 00For
CARILLON SERIES TRUST605,4520 00For
First Trust589,5860 00For
Prudential/PGIM577,7260 00For
JPMorgan554,4990 00For
JANUS INVESTMENT FUND428,3990 00For
Goldman Sachs357,8230 00For
Invesco352,1190 00For
Dimensional349,9760 00For
TIAA305,9380 00For
Allspring303,3050 00For
Jackson National297,7570 00For
Equitable274,8190 00For
Manager Directed Portfolios254,7200 00For
John Hancock246,2610 00For
AB DISCOVERY GROWTH FUND, INC.240,1760 00For
Brown Advisory Funds222,4140 00For
Aberdeen219,9120 00For

Showing the 25 largest of 137 asset managers. See all 137 in the interactive database.

8. To approve an amendment and restatement of the Company's 2018 Employee Stock Purchase Plan; and

COMPENSATIONMajority of the votes cast: yes

Meeting held 2025-05-21.

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 85,402,588AGAINST: 138,042

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The 2025 Plan was approved. • Approval of the Amended and Restated ESPP.”): 85,402,588 for, 138,042 against, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,000,000 outstanding shares: 86% for, 0.2% against (86% of the company cast a for/against vote).

The 85 asset managers below cast 100% of the shares they voted on this item FOR (26,883,083 for, 0 against).

FOR 100%
FOR: 26,883,083 (100.0%)
Largest asset managers voting on “To approve an amendment and restatement of the Company's 2018 Employee Stock Purchase Plan; and” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,187,5850 00For
Dodge & Cox4,444,4630 00For
State Street1,958,8150 00For
Fidelity1,848,6740 00For
T. Rowe Price1,123,7080 00For
Thrivent864,1570 00For
First Trust589,5860 00For
JANUS INVESTMENT FUND428,3990 00For
Goldman Sachs357,8230 00For
Invesco352,1190 00For
Dimensional349,9760 00For
TIAA305,9380 00For
Allspring303,3050 00For
Equitable274,8190 00For
AB DISCOVERY GROWTH FUND, INC.240,1760 00For
Aberdeen219,9120 00For
Lincoln Financial198,7990 00For
Eaton Vance196,7470 00For
FRANKLIN STRATEGIC SERIES166,6300 00For
Principal153,5010 00For
Voya144,2410 00For
American Century143,8890 00For
AIG/SunAmerica137,2050 00For
MFS132,5810 00For
GLENMEDE FUND INC126,1240 00For

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

9. TO APPROVE AN AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2018 EMPLOYEE STOCK PURCHASE PLAN.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2025-05-21.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 85,402,588AGAINST: 138,042

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The 2025 Plan was approved. • Approval of the Amended and Restated ESPP.”): 85,402,588 for, 138,042 against, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,000,000 outstanding shares: 86% for, 0.2% against (86% of the company cast a for/against vote).

The 60 asset managers below cast 99.6% of the shares they voted on this item FOR (13,828,529 for, 52,716 against).

FOR 99.6%
FOR: 13,828,529 (99.6%)AGAINST: 52,716 (0.4%)ABSTAIN: 0 (0.0%)
Largest asset managers voting on “TO APPROVE AN AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2018 EMPLOYEE STOCK PURCHASE PLAN.” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock7,784,3920 00For
Vanguard1,512,5390 00For
Charles Schwab762,8900 00For
CARILLON SERIES TRUST605,4520 00For
JPMorgan554,4990 00For
Prudential/PGIM508,826430 00For
Jackson National297,7570 00For
Manager Directed Portfolios254,7200 00For
John Hancock246,2610 00For
Brown Advisory Funds222,4140 00For
Bridge Builder Trust153,8010 00For
IMPAX FUNDS SERIES TRUST I100,0000 00For
Hartford95,3910 00For
AMG FUNDS90,6580 00For
MASTER INVESTMENT PORTFOLIO73,0790 00For
VanEck ETF Trust72,0620 00For
SEI65,0820 00For
PRIMECAP Odyssey Funds63,1100 00For
Brighthouse052,286 00Against
Integral Health Asset Management, LLC43,0230 00For
Six Circles Trust39,7230 00For
Mercer Funds39,0920 00For
Baird36,3490 00For
HUSSMAN INVESTMENT TRUST25,2000 00For
Russell Investments23,6150 00For

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

10. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-05-21.

98% fund support · no official result

FOR 90%8%

The 25 asset managers below cast 98% of the shares they voted on this item FOR (2,125,702 for, 51,830 against).

FOR: 2,125,702 (89.7%)AGAINST: 51,830 (2.2%)ABSTAIN: 193,343 (8.2%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JPMorgan1,775,7600 00For
APG Asset Management US Inc.224,8740 00For
Eversept Partners, LP00 167,2430Abstain
Empower49,1050 00For
Erste Asset Management GmbH00 26,1000Abstain
TD ASSET MANAGEMENT INC25,0410 00For
TOBAM22,7970 00For
Desjardins Global Asset Management Inc.015,340 00Against
Regime de rentes du Mouvement Desjardins014,614 00Against
Cardano Risk Management B.V.011,259 00Against
EFG Asset Management (North America) Corp.10,1490 00For
NORDEA INVESTMENT MANAGEMENT AB07,628 00Against
Vinva Investment Management Ltd5,2200 00For
WASHINGTON CAPITAL MANAGEMENT, INC4,4000 00For
OSSIAM02,989 00Against
GuideStone2,1880 00For
Metzler Asset Management GmbH2,0890 00For
Coyle Financial Counsel LLC1,0550 00For
SIERRA SUMMIT ADVISORS LLC1,0550 00For
HC CAPITAL TRUST8000 00For
DSM CAPITAL PARTNERS LLC7950 00For
Colony Family Offices, LLC2110 00For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma1470 00For
Jasper Ridge Partners, L.P.100 00For
UNIFIED SERIES TRUST60 00For

11. Amend Qualified Employee Stock Purchase Plan

COMPENSATION

Meeting held 2025-05-21.

100% fund support · no official result

FOR 23%ABSTAIN 77%

The 7 asset managers below cast 100% of the shares they voted on this item FOR (56,499 for, 0 against).

FOR: 56,499 (22.6%)ABSTAIN: 193,343 (77.4%)
Largest asset managers voting on “Amend Qualified Employee Stock Purchase Plan” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Eversept Partners, LP00 167,2430Abstain
Empower49,1050 00For
Erste Asset Management GmbH00 26,1000Abstain
WASHINGTON CAPITAL MANAGEMENT, INC4,4000 00For
GuideStone2,1880 00For
HC CAPITAL TRUST8000 00For
UNIFIED SERIES TRUST60 00For

12. Approve Omnibus Stock Plan

COMPENSATION

Meeting held 2025-05-21.

91% fund support · no official result

FOR 21%ABSTAIN 77%

The 7 asset managers below cast 91% of the shares they voted on this item FOR (51,299 for, 5,200 against).

FOR: 51,299 (20.5%)AGAINST: 5,200 (2.1%)ABSTAIN: 193,343 (77.4%)
Largest asset managers voting on “Approve Omnibus Stock Plan” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Eversept Partners, LP00 167,2430Abstain
Empower49,1050 00For
Erste Asset Management GmbH00 26,1000Abstain
WASHINGTON CAPITAL MANAGEMENT, INC04,400 00Against
GuideStone2,1880 00For
HC CAPITAL TRUST0800 00Against
UNIFIED SERIES TRUST60 00For

13. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

Meeting held 2025-05-21.

100% fund support · no official result

FOR 100%

The 5 asset managers below cast 100% of the shares they voted on this item FOR (78,199 for, 0 against).

FOR: 78,199 (100.0%)
Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Empower49,1050 00For
Erste Asset Management GmbH26,1000 00For
GuideStone2,1880 00For
HC CAPITAL TRUST8000 00For
UNIFIED SERIES TRUST60 00For

14. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-05-21.

100% fund support · no official result

FOR 100%

The 5 asset managers below cast 100% of the shares they voted on this item FOR (335,704 for, 0 against).

FOR: 335,704 (100.0%)
Largest asset managers voting on “14A Executive Compensation” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Sarissa Capital Management LP307,4340 00For
Simplify Exchange Traded Funds20,4840 00For
Focus Partners Wealth6,1650 00For
Claret Asset Management Corp1,4580 00For
MQS Management LLC1630 00For

15. Approval of the 2025 Equity Incentive Plan

COMPENSATION

Meeting held 2025-05-21.

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (14,395 for, 0 against).

FOR: 14,395 (100.0%)
Largest asset managers voting on “Approval of the 2025 Equity Incentive Plan” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Cardano Risk Management B.V.11,2590 00For
OSSIAM2,9890 00For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma1470 00For

16. Ratify Appointment of Independent Auditors

AUDIT-RELATED

Meeting held 2025-05-21.

67% fund support · no official result

FOR 67%AGAINST 33%

The 3 asset managers below cast 67% of the shares they voted on this item FOR (23,334 for, 11,259 against).

FOR: 23,334 (67.5%)AGAINST: 11,259 (32.5%)
Largest asset managers voting on “Ratify Appointment of Independent Auditors” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Simplify Exchange Traded Funds20,4840 00For
Cardano Risk Management B.V.011,259 00Against
AMERICAN PENSION INVESTORS TRUST2,8500 00For

17. An advisory vote on the compensation paid to the Company’s named executive officers

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-05-21.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (462,359 for, 0 against).

FOR: 462,359 (100.0%)
Largest asset managers voting on “An advisory vote on the compensation paid to the Company’s named executive officers” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fiera Capital Corp462,3590 00For
IPConcept (Luxemburg) S.A.00 00--

18. Adopt Incentive Stock Option Plan

COMPENSATION

Meeting held 2025-05-21.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (23,334 for, 0 against).

FOR: 23,334 (100.0%)
Largest asset managers voting on “Adopt Incentive Stock Option Plan” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Simplify Exchange Traded Funds20,4840 00For
AMERICAN PENSION INVESTORS TRUST2,8500 00For

19. Amend Employee Stock Purchase Plan

CAPITAL STRUCTUREMajority of the votes cast: yes

Meeting held 2025-05-21.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 85,402,588AGAINST: 138,042

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The 2025 Plan was approved. • Approval of the Amended and Restated ESPP.”): 85,402,588 for, 138,042 against, per its Form 8-K filed 2025-05-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,000,000 outstanding shares: 86% for, 0.2% against (86% of the company cast a for/against vote).

The 2 asset managers below cast 100% of the shares they voted on this item FOR (23,334 for, 0 against).

FOR 100%
FOR: 23,334 (100.0%)
Largest asset managers voting on “Amend Employee Stock Purchase Plan” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Simplify Exchange Traded Funds20,4840 00For
AMERICAN PENSION INVESTORS TRUST2,8500 00For

20. Amendment to the 2018 Employee Stock Purchase Plan

COMPENSATION

Meeting held 2025-05-21.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (11,406 for, 0 against).

FOR: 11,406 (100.0%)
Largest asset managers voting on “Amendment to the 2018 Employee Stock Purchase Plan” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Cardano Risk Management B.V.11,2590 00For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma1470 00For

21. DIRECTOR

DIRECTOR ELECTIONS

Meeting held 2025-05-21.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (10,905 for, 0 against).

FOR: 10,905 (100.0%)
Largest asset managers voting on “DIRECTOR” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
THOMPSON IM FUNDS INC9,7550 00For
Tidal Trust III1,1500 00For

22. Advisory vote on the compensation paid to the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-05-22 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%
FOR: 76,076,416AGAINST: 9,499,523

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the Amended 2020 Plan.”): 76,076,416 for, 9,499,523 against, per its Form 8-K filed 2024-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,000,000 outstanding shares: 77% for, 10% against (86% of the company cast a for/against vote).

The 2 asset managers below cast 100% of the shares they voted on this item FOR (812 for, 0 against).

FOR 100%
FOR: 812 (100.0%)
Largest asset managers voting on “Advisory vote on the compensation paid to the Company's named executive officers.” at NEUROCRINE BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
COLDSTREAM CAPITAL MANAGEMENT INC8120 00For
Echo45 Advisors LLC00 00--

Largest NEUROCRINE BIOSCIENCES INC. shareholders voting in 2024-2025

Ranked by the number of NEUROCRINE BIOSCIENCES INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 99,000,000 shares outstanding at the time of that meeting.

Top NEUROCRINE BIOSCIENCES INC. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1BlackRock 13.59%
2Vanguard 12.03%
3Dodge & Cox 9.81%
4State Street 6.63%
5T. Rowe Price 2.69%
6Fidelity 1.96%
7GEODE CAPITAL MANAGEMENT, LLC 1.95%
8Thrivent 1.76%
9Wellington 1.71%
10Charles Schwab 1.60%

Reported NEUROCRINE BIOSCIENCES INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

NEUROCRINE BIOSCIENCES INC. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
BlackRock 14.83% 13F
The Vanguard Group 10.23% DEF14A
Dodge & Cox 5.59% 13G
State Street 4.91% 13F
JPMorgan Chase 2.70% 13F
Renaissance Technologies 2.53% 13F
Wellington Management 2.12% 13F
Kevin C. Gorman, Ph.D. 1.57% DEF14A
T. Rowe Price 1.56% 13F
Morgan Stanley 1.53% 13F

Percentages above are of 99,000,000 shares outstanding, as reported by NEUROCRINE BIOSCIENCES INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NEUROCRINE BIOSCIENCES INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At NEUROCRINE BIOSCIENCES INC.'s shareholder meeting held 2025-05-21, in the 2024-2025 proxy season, 601 asset managers reported how they voted in their SEC Form N-PX filings, covering 5,860 separate fund positions. Their filings are grouped here into 22 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. NEUROCRINE BIOSCIENCES INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Advisory vote on the compensation paid to the Company's named executive officers. — the reporting funds cast 95% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

NEUROCRINE BIOSCIENCES INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.